查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2022-2029 年排卵預測器的全球市場
市場調查報告書
商品編碼
1153806

2022-2029 年排卵預測器的全球市場

Global Ovulation Predictors Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

排卵是每個月從卵巢中釋放一個卵子的生物學過程。排卵前，女性的身體通常在月經週期中期向血液中釋放大量黃體生成素 (LH)。排卵預測試劑盒檢測排卵前尿液中 LH 濃度的增加。這些測試預測排卵時間和生育高峰期。排卵前檢測試劑盒根據尿液中的 LH 濃度、唾液中的電解質濃度或用戶的基礎體溫來預測排卵。排卵預測因子可以在您自己舒適的家中進行測試，並有助於檢測黃體生成素和另一種類似激素的物質雌激素。

市場動態

妊娠並發症的增加推動了市場、易用性和測試的可及性、妊娠管理和女性健康的改善、技術的進步以獲得可靠和準確的結果。

預計排卵預測技術的進步將推動市場增長。

希望懷孕的女性越來越多地使用專為智能手機和類似設備設計的生育力追蹤軟件應用程序 (apps) 來計時性交。許多懷孕應用程序僅根據用戶的數據進行預測，例如最近的月經日和月經週期。然而，事實證明，僅憑日曆無法檢測易孕期窗口或排卵期。一項研究發現，週期跟蹤應用程序只有 21% 的機會正確識別女性的排卵日期。因此，人們認為結合排卵測試試劑盒的準確性和應用程序的易用性來確定可能的排卵日的方法將對希望懷孕的女性有用。例如，Clearblue Connected 排卵測試系統（Swiss Precision Diagnostics [SPD] GmbH，瑞士日內瓦）專供女性家庭使用。通過跟蹤排卵前 LH 和 E3G 水平的升高，可以可靠地預測生育期。 21 測試系統可以通過藍牙連接到用戶的智能手機，軟件記錄女性的月經週期並使用該信息來確定何時進行尿液測試。尿液激素測試在三種程度之一進行：當激素水平處於基線時較低，當監測器檢測到 E3G 水平升高時較高，當檢測到 LH 激增時達到生育高峰。它反映了什麼因此，上述因素有望在預測期內推動市場。

約束

排卵測試不能確認排卵，但可以確定排卵前的黃體生成素。如果您正在使用促排卵藥物，排卵檢測試劑盒將無法正常工作。 40 歲以上的女性或已經絕經的女性不能使用排卵試紙。對使用排卵檢測試劑盒的認識不足以及使用這些設備的優勢是預計在預測期內阻礙市場的因素。

COVID-19 影響分析

COVID-19 大流行是人類在上個世紀面臨的最具破壞性的健康危機。缺乏可行的藥物選擇阻礙了與這種疾病的鬥爭。目前，尚無臨床許可的疫苗或藥物可用於治療 COVID-19，並且對新療法的不懈探索正以大流行的速度進行。此外，由於在家工作的文化，人們大部分時間都在家裡並且不在工作。此外，在家工作已成為主流，讓我從工作中解脫出來，讓我可以與家人共度美好時光。這一時期受孕率上升，排卵試紙市場活躍。由於當地零售商開門營業，排卵試紙並不短缺，但由於排卵試紙產量低，排卵試紙市場的需求下降。在 COVID-19 之後，排卵測試市場有望快速增長。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第四章市場動態

  • 市場影響因素
    • 司機
      • 預計排卵預測技術的進步將推動市場增長。
    • 約束因素
      • 對使用排卵檢測試劑盒的認識不足預計會阻礙市場增長。
    • 市場機會
    • 影響分析

第五章行業分析

  • 搬運工的五種力量
  • 供應鏈
  • 定價分析

第 6 章 COVID-19 分析

  • COVID-19 市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按產品類型

  • 尿液排卵測試試劑盒
    • 試紙法
    • 中游法
  • 唾液排卵測試
  • 唾液腺排卵測試試劑盒

最終用戶第 8 章

  • 醫院
  • 診所
  • 診斷中心
  • 生育中心
  • 家庭護理
  • 其他

第9章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第10章競爭格局

  • 競爭場景
  • 市場情況/份額分析
  • 併購分析

第11章公司簡介

  • Swiss Precision Diagnostics GmbH
    • 公司簡介
    • 產品組合和說明
    • 主要亮點
    • 財務摘要
  • Church & Dwight Co. Inc.
  • Prestige Consumer Healthcare, Inc.
  • Hilin Life Products
  • Fairhaven Health LLC
  • Geratherm Medical AG
  • Piramal Enterprises Ltd.
  • Clearblue
  • Fertility Focus Limited
  • Accuquik

第12章 排卵預測器的全球市場-DataM

簡介目錄
Product Code: DMCD1075

Market Overview

The global ovulation predictors market size was valued around US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of YY% during the forecast period (2022-2029).

Ovulation is a biological process of releasing eggs from the ovary every month. Before ovulation, the female body releases luteinizing hormones (LH) in a large amount into the blood, which usually takes place in the middle of the menstrual cycle. Ovulation predictors detect a rise in LH in urine as its concentration increases before the ovulation phase. These tests predict ovulation time and peak fertility. Ovulation predictors are based on LH levels in urine, electrolyte levels in saliva, or the user's basal body temperature. Ovulation predictors provide the comfort of testing at home and help in the detection of luteinizing hormone along with another hormone-like, estrogen.

Market Dynamics

A rise in pregnancy complications drives the market, easy usage and availability of tests, increased pregnancy management and women's health, and technological advancements for reliable and accurate results.

Technological advancement in ovulation predictors is expected to drive market growth.

Fertility-tracking software applications (apps) designed for smartphones and similar devices are increasingly used to time intercourse by women seeking to conceive. Most fertility apps provide forecasts based entirely on user data, such as the latest menstrual period date and cycle duration. However, using a calendar alone to detect the viable window and ovulation has proved ineffective. One study discovered that by utilizing cycle-tracking apps, the probability of correctly identifying a woman's day of ovulation was only 21%. As a result, a way of determining the viable window that combines the precision of an ovulation test with the ease of an app could be useful to women trying to conceive. For instance, The Clearblue Connected Ovulation Test System (Swiss Precision Diagnostics [SPD] GmbH, Geneva, Switzerland) is intended for home use by women. It may reliably forecast the fertile window by tracking spikes in LH and E3G levels that precede ovulation. 21 The test system can link to the user's smartphone through Bluetooth, where the software records the woman's menstrual cycle and uses this information to determine when to perform the pee tests. The urine hormone test reflects one of three degrees of fertility: low when hormone levels are at baseline, high when the monitor detects increasing E3G levels, and peak fertility when the LH surge is detected. Thus, from the above factors, the market is expected to drive in the forecast period.

Restraint:

However, the ovulation test doesn't confirm ovulation; it simply identifies the Luteinizing hormone that precedes ovulation. If the User is on any fertility drugs, the ovulation test does not function properly. The ovulation test does not function for women over 40 or already approaching menopause. Low awareness regarding using Ovulation test kits and the benefits of using devices are the factors the market is expected to get hampered in the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic is the most devastating health crisis that humanity has faced in the last century. The lack of viable medicinal options has hampered the fight against the disease. There is currently no clinically licensed vaccine or medicine to treat COVID-19, and the continuous hunt for a novel cure is moving at a pandemic pace. Moreover, because of the work-from-home culture, people mainly stayed at home and had an extended break from work. The respite from their hectic schedules allowed them to spend quality time with their families. Pregnancy rates increased during this time, which boosted the ovulation test kit market. There was no shortage of ovulation test kits because local retailers were open; nonetheless, the low output of ovulation test kits reduced demand in the ovulation test market. Following the post-COVID-19 situation, the ovulation kit test market will likely grow rapidly.

Segment Analysis

Urine-Based Ovulation Test Kit segment is estimated to hold the largest market share in ovulation predictors market.

The urine-based ovulation test kit segment accounted for the largest market share in 2021. The segment benefits because these are more accurate than salivary ferning kits, but they're not foolproof. These are very easy to use and can be bought bulk from any supermarket. Urine-Based Test Ovulation Test Kit comes with test strips or sticks. For instance, Clearblue Easy Fertility Monitor, this monitor detects two hormones, LH and estrogen. It allows for detection on more fertile days than paper tests. Therefore, it has increased the demand for the urine-based ovulation test kit. Thus, from the above factors, the market segment is accounted for the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global ovulation predictors market

North America accounted for the largest market share in 2021. Technological advancements in the ovulation predictors, higher adoption of the tests, partnerships and collaborations by the key market players in the region are the factors to drive the market in the forecast period. For instance, a team of Brigham researchers has created a low-cost smartphone gadget that can predict ovulation and aid in family planning using the latest technological advancement. The instrument automatically recognizes fern-like patterns-a hallmark of ovulation-in a saliva sample using microfluidic technology (in which fluids flow through small channels), artificial intelligence (AI), and the pervasiveness of smartphones. The scientists tested the device's effectiveness in the lab using artificial saliva. They validated the results with saliva samples from six patients, achieving higher than 99 percent accuracy in predicting ovulation.

Additionally, through the Real Talk with Conceiving Hood Campaign, actress Jordana Brewster collaborated with Clearblue in April 2021 to raise awareness about the difficulty in conceiving and fertility in women. Therefore, it has increased the adoption of ovulation predictors in the region. Thus, from the above factors, the North America region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the ovulation predictors market are: Swiss Precision Diagnostics GmbH, Hilin Life Products, Fairhaven Health LLC, Geratherm Medical AG, Church & Dwight Co. Inc., Prestige Consumer Healthcare, Inc., Piramal Enterprises Ltd., Clearblue, Fertility Focus Limited, and Accuquik.

Swiss Precision Diagnostics GmbH:

Overview:

Swiss Precision Diagnostics (SPD) was formed as a joint venture between Procter & Gamble (P&G) and Alere (now a part of the Abbott group, since October 2017) to create, using its parent companies complementary strengths, one of the world's foremost organizations in consumer diagnostics. Alere (a wholly owned subsidiary of Abbott) is among the world's leading providers of innovative diagnostic products, renowned for their proven reliability in the professional management of women's health and chronic and infectious disease. SPD is currently a leading home pregnancy and fertility/ovulation test supplier. The company has a strong focus on women's reproductive health, and its goals are in the continuing supply of diagnostic products which are accurate, simple and affordable.

Product Portfolio:

Clearblue Advanced Fertility Monitor: Clearblue Advanced Fertility Monitor is one of the most advanced home method proven to increase a woman's chance of conceiving by up to more than 85% in the first two cycles of use. The monitor reliably identifies the days of the cycle when women are most likely to conceive - these are the days before the day of ovulation when an egg is released from the ovary. Having sexual intercourse on the day of ovulation and the days leading up to ovulation provides the best chances of conceiving. The product consists of a handheld monitor and disposable test sticks. The monitor tells the woman when to test and indicates her level of fertility each day. Two hormones are monitored - estrone-3-glucuronide (E3G), a urinary metabolite of estrogen and luteinizing hormone (LH). By monitoring both hormones, the monitor can identify more fertile days than any other home method. It is a unique innovation for couples who are proactively planning pregnancy. It is simple to use, completely natural and 99% accurate in detecting the LH surge.

The global ovulation predictors market report would provide an access to an approx. 45+ market data table, 40+ figures and 180 pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Technological advancement in ovulation predictors is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. Low awareness regarding using Ovulation test kits is expected to hamper market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Supply Chain
  • 5.3. Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Urine-Based Ovulation Test Kit*
      • 7.2.1.1. Test Strip Method
      • 7.2.1.2. Introduction
      • 7.2.1.3. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
      • 7.2.1.4. Mid-Stream Method
  • 7.3. Saliva-Based Ovulation Test Kit
  • 7.4. Salivary Ferning Ovulation Test Kits

8. By End user

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 8.1.2. Market Attractiveness Index, By End user
  • 8.2. Hospitals*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Clinics
  • 8.4. Diagnostic Centers
  • 8.5. Fertility Centers
  • 8.6. Homecare
  • 8.7. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Swiss Precision Diagnostics GmbH*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Church & Dwight Co. Inc.
  • 11.3. Prestige Consumer Healthcare, Inc.
  • 11.4. Hilin Life Products
  • 11.5. Fairhaven Health LLC
  • 11.6. Geratherm Medical AG
  • 11.7. Piramal Enterprises Ltd.
  • 11.8. Clearblue
  • 11.9. Fertility Focus Limited
  • 11.10. Accuquik

LIST NOT EXHAUSTIVE

12. Global Ovulation Predictors Market - DataM

  • 12.1. Appendix
  • 12.2. About Us and Applications
  • 12.3. Contact Us